Literature DB >> 20703254

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma.

P M Bhende, S I Park, M S Lim, D P Dittmer, B Damania.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20703254      PMCID： PMC3027218          DOI： 10.1038/leu.2010.154

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Authors:  Kojo S J Elenitoba-Johnson; Stephen D Jenson; Robert T Abbott; Robert A Palais; Sandra D Bohling; Zhaosheng Lin; Sheryl Tripp; Paul J Shami; Lai Y Wang; Robert W Coupland; Rena Buckstein; Bayardo Perez-Ordonez; Sherrie L Perkins; Ian D Dube; Megan S Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

2.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

3.  p53 mutations are associated with histologic transformation of follicular lymphoma.

Authors:  F Lo Coco; G Gaidano; D C Louie; K Offit; R S Chaganti; R Dalla-Favera
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

4.  Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma.

Authors:  J J Yunis; M M Oken; M E Kaplan; K M Ensrud; R R Howe; A Theologides
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

5.  Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.

Authors:  Sang-Hoon Sin; Debasmita Roy; Ling Wang; Michelle R Staudt; Farnaz D Fakhari; Dhavalkumar D Patel; David Henry; William J Harrington; Blossom A Damania; Dirk P Dittmer
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

6.  p53 mutation is associated with progression in follicular lymphomas.

Authors:  C A Sander; T Yano; H M Clark; C Harris; D L Longo; E S Jaffe; M Raffeld
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

7.  Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray.

Authors:  Hongbin Zha; Mark Raffeld; Lu Charboneau; Stefania Pittaluga; Larry W Kwak; Emanuel Petricoin; Lance A Liotta; Elaine S Jaffe
Journal:  Lab Invest       Date:  2004-02       Impact factor: 5.662

8.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive.

Authors:  Estela Jacinto; Robbie Loewith; Anja Schmidt; Shuo Lin; Markus A Rüegg; Alan Hall; Michael N Hall
Journal:  Nat Cell Biol       Date:  2004-10-03       Impact factor: 28.824

9.  The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.

Authors:  Anna Dubrovska; Sungeun Kim; Richard J Salamone; John R Walker; Sauveur-Michel Maira; Carlos García-Echeverría; Peter G Schultz; Venkateshwar A Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-30       Impact factor: 11.205

Review 10.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582
View more
  35 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

2.  Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma.

Authors:  Penny Anders; Prasanna M Bhende; Michael Foote; Dirk P Dittmer; Steven I Park; Blossom Damania
Journal:  Leuk Lymphoma       Date:  2014-06-06

3.  Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.

Authors:  Minh Ngoc Duong; Eva-Laure Matera; Doriane Mathé; Anne Evesque; Sandrine Valsesia-Wittmann; Béatrice Clémenceau; Charles Dumontet
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 4.  Mammalian target of rapamycin: a central node of complex signaling cascades.

Authors:  Yoh Dobashi; Yasutaka Watanabe; Chihiro Miwa; Sakae Suzuki; Shinichiro Koyama
Journal:  Int J Clin Exp Pathol       Date:  2011-06-14

Review 5.  The PI3K pathway in B cell metabolism.

Authors:  Julia Jellusova; Robert C Rickert
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-08-05       Impact factor: 8.250

6.  Rapalogs in viral cancers.

Authors:  Dirk P Dittmer; Aadra P Bhatt; Blossom Damania
Journal:  Expert Opin Investig Drugs       Date:  2012-01-04       Impact factor: 6.206

Review 7.  Current clinical development of PI3K pathway inhibitors in glioblastoma.

Authors:  Patrick Y Wen; Eudocia Q Lee; David A Reardon; Keith L Ligon; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2012-05-22       Impact factor: 12.300

8.  Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.

Authors:  Chie Ishikawa; Masachika Senba; Naoki Mori
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 9.  Management of indolent lymphoma: where are we now and where are we going.

Authors:  Matthew A Lunning; Julie M Vose
Journal:  Blood Rev       Date:  2012-10-09       Impact factor: 8.250

Review 10.  Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Authors:  Elias Jabbour; Oliver G Ottmann; Michael Deininger; Andreas Hochhaus
Journal:  Haematologica       Date:  2014-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.